Specialized CRO ChanTest specializes in ion channel focused Contract Research Organization (CRO) services, catering to global pharma and biotech companies. This expertise presents an opportunity to position the company as a key partner for clients seeking high-value solutions in ion channel and GPCR biology.

Comprehensive Service Portfolio With an extensive library of validated ion channel cell lines and a wide range of pre-clinical cardiac risk assessment services, ChanTest offers one of the most comprehensive service portfolios in the industry. This breadth of offerings can be leveraged to attract clients looking for integrated solutions in safety testing and drug development.

Trusted Provider ChanTest has been recognized as the 'most trusted and most used fee-for-service provider' for ion channel screening. This reputation for reliability and quality positions the company as a preferred partner for pharmaceutical and biotechnology companies seeking dependable and efficient contract research services.

Global Reach Since its inception in 1998, ChanTest has worked with over 300 global pharmaceutical and biotechnology companies. This established network presents an opportunity to expand sales by tapping into existing relationships and leveraging the company's experience in serving the drug discovery and development needs of a diverse client base.

Revenue Potential With a revenue ranging from $100 million to $1 billion, ChanTest operates in a financially robust position. This financial stability not only signifies a strong market presence but also indicates the potential for significant sales growth and investment in expanding services to drive revenue further.